<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940804-2-00091</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  September 6, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <DOCTITLE>[Docket No. 94N&hyph;0287]</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Glaxo, Inc., et al.; Withdrawal of Approval of 13 Abbreviated Antibiotic Applications and 2 Abbreviated New Drug Applications</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is withdrawing approval of 13 abbreviated antibiotic applications (AADA's) and 2 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no being longer marketed and requested that the approval of the applications be withdrawn. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  September 6, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->   <!-- PJG 0012 frnewline --> Lola E. Batson,  <!-- PJG 0012 frnewline --> Center for Drug Evaluation and Research (HFD&hyph;360),  <!-- PJG 0012 frnewline --> Food and Drug Administration,  <!-- PJG 0012 frnewline --> 7500 Standish Pl.,  <!-- PJG 0012 frnewline --> Rockville, MD 20855,  <!-- PJG 0012 frnewline --> 301&hyph;594&hyph;1038. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The holders of the applications listed in the table below have informed FDA that these drug products are no longer being marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1,i1,s35,r100,r100 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Application no. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Drug <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Applicant <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> AADA  <!-- PJG 0012 frnewline --> 61&hyph;231 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Crystalline Penicillin G Potassium (bulk)  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Glaxo, Inc.,  <!-- PJG 0012 frnewline --> Five Moore Dr.,  <!-- PJG 0012 frnewline --> P.O. Box 13358,  <!-- PJG 0012 frnewline --> Research Triangle  <!-- PJG 0012 frnewline --> Park, NC 27709.  <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 61&hyph;232  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Crystalline Penicillin G Sodium (bulk)  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Do.  <!-- PJG 0012 frnewline --> AADA 61&hyph;324  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Penicillin G Procaine (bulk) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Do.  <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 61&hyph;491 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Penicillin G Procaine Type ``A'' (bulk)  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Do. <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 61&hyph;705 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Tetracycline Hydrochloride Tablets, U.S.P., 250 milligrams (mg) and 500 mg <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> The Upjohn Co.,  <!-- PJG 0012 frnewline --> 7000 Portage Rd.,  <!-- PJG 0012 frnewline --> Kalamazoo, MI  <!-- PJG 0012 frnewline --> 49001. <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 61&hyph;743 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Erythromycin Stearate Tablets, U.S.P., 250 mg <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Purepac Pharmaceutical Co.,  <!-- PJG 0012 frnewline -->  200 Elmora Ave.,  <!-- PJG 0012 frnewline -->  Elizabeth, NJ 07207.  <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 61&hyph;945 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Sterile Penicillin G Potassium Buffered (bulk) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Glaxo, Inc. <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 629&hyph;053 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Rifampin, U.S.P., (nonsterile bulk) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Marion Merrill Dow, Inc.,  <!-- PJG 0012 frnewline --> Marion Park Dr.,  <!-- PJG 0012 frnewline --> Kansas City, MO 64134&hyph;0627.  <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 62&hyph;213 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Sterile Penicillin G Sodium Buffered (bulk) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Glaxo, Inc. <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 62&hyph;297 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Ampicillin for Oral Squibb, Suspension,U.S.P., 125 mg/5 milliliters (mL) and 250 mg/5 mL  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Bristol-Myers Co.,  <!-- PJG 0012 frnewline -->  P.O. Box 4755,  <!-- PJG 0012 frnewline -->  Syracuse, NY 13221&hyph;4755.  <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 62&hyph;399  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension, U.S.P.  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Pharmafair, Inc.,  <!-- PJG 0012 frnewline -->  110 Kennedy Dr.,  <!-- PJG 0012 frnewline -->  Hauppauge, NY 11788.  <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 62&hyph;404 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Sterile Cephalothin Sodium, U.S.P. (bulk) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Glaxo, Inc. <!-- PJG 0012 frnewline --> AADA  <!-- PJG 0012 frnewline --> 62&hyph;435 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Cephalothin Sodium for Injection, U.S.P. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Do. <!-- PJG 0012 frnewline --> ANDA  <!-- PJG 0012 frnewline --> 88&hyph;101 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Naphazoline Hydrochloride Ophthalmic Solution, U.S.P., 0.1% <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Pharmafair, Inc. <!-- PJG 0012 frnewline --> ANDA  <!-- PJG 0012 frnewline --> 88&hyph;230 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Tropicamide Ophthalmic Solution, U.S.P., 1% <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Do. <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 6, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: July 26, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Janet Woodcock, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, Center for Drug Evaluation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;18971 Filed 8&hyph;3&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            